BRAF-V600E Mutant Metastatic Colorectal Cancer: BRAVE Trial

We are studying a combination of encorafenib, cetuximab, and bevacizumab for patients with BRAF-V600E mutated metastatic colorectal cancer who have not responded to previous treatments. The trial aims to evaluate the safety and effectiveness of this treatment approach.

6-12 months≤5 visitsEfficacy phase (II)No PlaceboStandard MedicinesOralInjectionOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Braftovi
Braftovi is a cancer medicine used to treat certain advanced melanomas and some colorectal cancers that have a specific genetic mutation.
Erbitux
Erbitux is a cancer treatment used to help slow the growth of certain colorectal and head and neck cancers.
Mvasi
Mvasi is a cancer medicine used to treat several types of tumors by blocking the growth of blood vessels that feed the tumor.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Bevacizumab
Bevacizumab is a substance that blocks formation of new blood vessels to treat certain cancers and eye conditions caused by abnormal vessel growth.
Cetuximab
Cetuximab is a substance that targets a protein on cancer cells to help slow or stop growth in colorectal and head and neck cancers.
Encorafenib
Encorafenib is a substance that targets cancer cells with a specific BRAF gene mutation to help slow tumor growth.

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Abevmy
Alymsys
Avastin

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Complexo Hospitalario Universitario A Coruna
ONCOLOGIA
A Coruña, Spain
Hospital De La Santa Creu I Sant Pau
ONCOLOGIA
Barbastro, Spain
Hospital Del Mar
ONCOLOGIA
Barcelona, Spain
Sponsor: Vall D Hebron Institute Of Oncology
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.